Abstract
Increasing evidence supports GnRH agonists to be an effective treatment to preserve ovarian function during chemotherapy, but the initial flare-up of FSH during the first week after GnRH agonist application still limits its use. The combination of GnRH agonists with GnRH antagonists might solve this problem to some extent as the addition of GnRH antagonists at least significantly reduces the FSH flare-up.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Publication types
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use
-
Drug Therapy, Combination
-
Estradiol / blood
-
Female
-
Fertility*
-
Follicle Stimulating Hormone / blood*
-
Gonadotropin-Releasing Hormone / agonists*
-
Gonadotropin-Releasing Hormone / antagonists & inhibitors*
-
Humans
-
Infertility, Female / blood
-
Infertility, Female / drug therapy*
-
Infertility, Female / etiology
-
Luteinizing Hormone / blood
-
Neoplasms / complications*
-
Neoplasms / drug therapy
-
Treatment Outcome
-
Young Adult
Substances
-
Antineoplastic Agents
-
Gonadotropin-Releasing Hormone
-
Estradiol
-
Luteinizing Hormone
-
Follicle Stimulating Hormone